TacticScaleWhat GuangYuYuan Chinese Herbal Medicine (广誉远) Does & How It Makes Money (600771.SS)
Updated October 2026 · reflects GuangYuYuan Chinese Herbal Medicine's latest reported financials
Chinese maker of traditional herbal medicines and health wine. The company makes money by manufacturing traditional Chinese medicine products and health wine and selling them in many dosage forms.
How GuangYuYuan Chinese Herbal Medicine makes money
The company makes money by manufacturing traditional Chinese medicine products and health wine and selling them in many dosage forms.
What GuangYuYuan Chinese Herbal Medicine does
GuangYuYuan Chinese Herbal Medicine Co., Ltd. makes and sells traditional Chinese medicinal products. It has three product lines: traditional Chinese medicine, premium (fine) Chinese medicine and health wine. It makes them in many dosage forms, including pills, powders, tablets, hard capsules, granules and compound preparations. The company was founded in 1996 and is based in Taiyuan, China. It was formerly called Topsun Science And Technology Co Ltd. and took its current name in July 2013, which put its herbal medicine business at the center of its identity. It is classified as a general drug manufacturer in the healthcare sector.
Products & services
- Traditional Chinese medicine
- Fine (premium) Chinese medicine
- Health wine
- Herbal pills and powders
- Tablets, hard capsules and granules
- Compound herbal preparations
广誉远是做什么的？
广誉远中药股份有限公司主要生产和销售中药产品。产品分为传统中药、精品中药和保健酒三类，剂型包括丸剂、散剂、片剂、硬胶囊、颗粒剂和复方制剂等。 公司成立于1996年，总部位于山西太原。公司原名东盛科技股份有限公司，2013年7月更名为广誉远中药股份有限公司，以中药为核心业务。公司属于医疗保健行业中的综合制药类企业。
What is GuangYuYuan Chinese Herbal Medicine worth?
On an owner-earnings DCF, GuangYuYuan Chinese Herbal Medicine's most-likely value is about ¥7 versus a recent price near ¥14 (100% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥4) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Shijiazhuang Yiling Pharmaceutical (002603.SZ) · Guangzhou Baiyunshan Pharmaceutical (600332.SS) · Zhejiang Tianyu Pharmaceutical (300702.SZ) · Yunnan Baiyao (000538.SZ)